Andere Sprachen Avalo Therapeutics, Inc.

Aktien

A3E2FR

US05338F3064

AVTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.05.2024			% 5 Tage	% 1. Jan.
13,25 ^USD	-1,92 %		-22,61 %	+45,60 %

16.04.	AVALO THERAPEUTICS, INC. : Von Oppenheimer zum Kaufen aufgerüstet	ZM
29.03.	Avalo Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Stock Futures -2-	17.04.
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors	02.04.
Avalo Reports 2023 Financial Results and Provides Business Updates	01.04.
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Avalo Reports 2023 Financial Results and Provides Business Updates	29.03.
Sector Update: Health Care Stocks Rise Late Afternoon	28.03.
Top Midday Gainers	28.03.
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	28.03.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	28.03.
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data	28.03.
Top Premarket Gainers	28.03.
Avalo Therapeutics, Inc. announced that it has received $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, BVF Partners L.P., RA Capital Management, L.P., Commodore Capital LP, Petrichor Holdings, LLC	28.03.
Avalo Therapeutics, Inc. acquired AlmataBio, Inc. for $42.5 million.	28.03.
Avalo Therapeutics Shares Triple After Acquisition of AlmataBio, Private Placement Financing of Up to $185 Million	27.03.
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million	27.03.
Avalo Therapeutics, Inc. Announces Board Appointments	27.03.
North American Morning Briefing : Stocks Edge -2-	27.03.
Avalo Therapeutics, Inc. announced that it expects to receive $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, Commodore Capital, BVF Partners L.P., Petrichor Energy Inc., RA Capital Management, L.P.	27.03.
Avalo Therapeutics Plans 1-for-240 Reverse Stock Split	27.12.
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split	27.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Avalo Therapeutics, Inc.

Aktien

A3E2FR

US05338F3064

AVTX

Andere Sprachen

Filter